Open Access

Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report

  • Authors:
    • Tao Wu
    • Jinmao Zhou
    • Cunbang Wang
    • Binbin Wang
    • Shuting Zhang
    • Hai Bai
  • View Affiliations

  • Published online on: October 9, 2017     https://doi.org/10.3892/ol.2017.7151
  • Pages:7318-7322
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

0

Abstract

Multiple myeloma (MM) is a common B‑cell hematological malignancy in the clinic. Bortezomib is the first‑in‑class proteasome inhibitor that has been approved for the treatment of patients with MM in the bone marrow. The present study report the case of an 83‑year‑old man who showed marked weakness, fatigue and a poor appetite. The patient was admitted to the Department of Nephrology due to severe renal impairment (RI). Immunofixation electrophoresis indicated a λ light chain‑positive status. There were 19.2% plasmablasts and proplasmacytes in the bone marrow. Positivity for the cell surface markers cluster of differentiation (CD)13, CD33, CD38 and human leukocyte antigen‑antigen D‑related was detected by flow cytometry. The patient was diagnosed with MM, λ light chain type, stage IIIB, and received bortezomib and dexamethasone regimen chemotherapy. RI was improved following the chemotherapy, and plasmablasts and proplasmacytes were almost eliminated. The Hb level was maintained at ~90 g/l. Overall, the present case report suggests that bortezomib may be safe and effective for elderly patients, even those >80 years of age, with severe RI.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wu, T., Zhou, J., Wang, C., Wang, B., Zhang, S., & Bai, H. (2017). Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report. Oncology Letters, 14, 7318-7322. https://doi.org/10.3892/ol.2017.7151
MLA
Wu, T., Zhou, J., Wang, C., Wang, B., Zhang, S., Bai, H."Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report". Oncology Letters 14.6 (2017): 7318-7322.
Chicago
Wu, T., Zhou, J., Wang, C., Wang, B., Zhang, S., Bai, H."Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report". Oncology Letters 14, no. 6 (2017): 7318-7322. https://doi.org/10.3892/ol.2017.7151